Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefan Walzer

Showing results (1-10 of 46) with videos related to

Pageof 5
Sort By:
Therapeutics and Clinical Risk Management|March 25, 2008
What do parents want from their child's asthma treatment?Stefan Walzer
Vascular Health and Risk Management|August 21, 2007
Early retirement and the influence on healthcare budgets and insurance premiums in a diabetes populationStefan Walzer
Therapeutics and Clinical Risk Management|March 25, 2008
Willingness-to-pay for caregivers of children with asthma or wheezing conditionsStefan Walzer, Peter Zweifel
Algorithmica|September 23, 2025
ShockHash: Near Optimal-Space Minimal Perfect Hashing Beyond Brute-ForceHans-Peter Lehmann, Peter Sanders, Stefan Walzer
Health Policy (Amsterdam, Netherlands)|July 26, 2014
Evaluation of a possible predictor for Federal Joint Committee decisions on early benefit assessments according to the German act on the reform of the market for medicinal productsBjörn Schwander, Kurt Banz, Klaus Kaier, et al.
Clinicoeconomics and Outcomes Research : CEOR|March 21, 2014
Health economic analyses in medical nutrition: a systematic literature reviewStefan Walzer, Daniel Droeschel, Mark Nuijten, et al.
Clinicoeconomics and Outcomes Research : CEOR|May 31, 2014
Health economics evidence for medical nutrition: are these interventions value for money in integrated care?Stefan Walzer, Daniel Droeschel, Mark Nuijten, et al.
European Journal of Cancer (Oxford, England : 1990)|March 13, 2013
Effects of erlotinib first-line maintenance therapy versus placebo on the health-related quality of life of patients with metastatic non-small-cell lung cancerErzsébet Juhász, Joo-Hang Kim, Gaëlle Klingelschmitt, et al.
Lung Cancer (Amsterdam, Netherlands)|August 24, 2010
Cost-effectiveness analysis of bevacizumab versus pemetrexed for advanced non-squamous NSCLC in ItalyGiovanni Giuliani, Francesco Grossi, Filippo de Marinis, et al.
Clinicoeconomics and Outcomes Research : CEOR|August 19, 2016
Administrative risk quantification of subcutaneous and intravenous therapies in Italian centers utilizing the Failure Mode and Effects Analysis approachClemente Ponzetti, Monica Canciani, Massimo Farina, et al.
Pageof 5

Showing results (1-10 of 46) with videos related to

Sort By:
Pageof 5
Therapeutics and Clinical Risk Management|March 25, 2008
What do parents want from their child's asthma treatment?Stefan Walzer
Vascular Health and Risk Management|August 21, 2007
Early retirement and the influence on healthcare budgets and insurance premiums in a diabetes populationStefan Walzer
Therapeutics and Clinical Risk Management|March 25, 2008
Willingness-to-pay for caregivers of children with asthma or wheezing conditionsStefan Walzer, Peter Zweifel
Algorithmica|September 23, 2025
ShockHash: Near Optimal-Space Minimal Perfect Hashing Beyond Brute-ForceHans-Peter Lehmann, Peter Sanders, Stefan Walzer
Health Policy (Amsterdam, Netherlands)|July 26, 2014
Evaluation of a possible predictor for Federal Joint Committee decisions on early benefit assessments according to the German act on the reform of the market for medicinal productsBjörn Schwander, Kurt Banz, Klaus Kaier, et al.
Clinicoeconomics and Outcomes Research : CEOR|March 21, 2014
Health economic analyses in medical nutrition: a systematic literature reviewStefan Walzer, Daniel Droeschel, Mark Nuijten, et al.
Clinicoeconomics and Outcomes Research : CEOR|May 31, 2014
Health economics evidence for medical nutrition: are these interventions value for money in integrated care?Stefan Walzer, Daniel Droeschel, Mark Nuijten, et al.
European Journal of Cancer (Oxford, England : 1990)|March 13, 2013
Effects of erlotinib first-line maintenance therapy versus placebo on the health-related quality of life of patients with metastatic non-small-cell lung cancerErzsébet Juhász, Joo-Hang Kim, Gaëlle Klingelschmitt, et al.
Lung Cancer (Amsterdam, Netherlands)|August 24, 2010
Cost-effectiveness analysis of bevacizumab versus pemetrexed for advanced non-squamous NSCLC in ItalyGiovanni Giuliani, Francesco Grossi, Filippo de Marinis, et al.
Clinicoeconomics and Outcomes Research : CEOR|August 19, 2016
Administrative risk quantification of subcutaneous and intravenous therapies in Italian centers utilizing the Failure Mode and Effects Analysis approachClemente Ponzetti, Monica Canciani, Massimo Farina, et al.
Pageof 5